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Interactions between bone and the reproductive
system have until now been thought to be limited to
the regulation of bone remodeling by the gonads.
We now show that, in males, bone acts as a regulator
of fertility. Using coculture assays, we demonstrate
that osteoblasts are able to induce testosterone
production by the testes, though they fail to influence
estrogen production by the ovaries. Analyses of cell-
specific loss- and gain-of-function models reveal
that the osteoblast-derived hormone osteocalcin
performs this endocrine function. By binding to a G
protein-coupled receptor expressed in the Leydig
cells of the testes, osteocalcin regulates in a CREB-
dependent manner the expression of enzymes that
is required for testosterone synthesis, promoting
germ cell survival. This study expands the physiolog-
ical repertoire of osteocalcin and provides the first
evidence that the skeleton is an endocrine regulator
of reproduction.INTRODUCTION
Bone is a dynamic tissue undergoing modeling during child-
hood and remodeling throughout adulthood (Harada and
Rodan, 2003; Rodan and Martin, 2000). These two processes,
referred to hereafter as bone (re)modeling, are characterized
by the succession of resorption of mineralized bone by osteo-
clasts and de novo formation by osteoblasts. Bone (re)
modeling is regulated locally by cytokines produced by bone
cells and systemically by hormones and neuropeptides (Harada
and Rodan, 2003; Karsenty et al., 2009). One of the most
powerful hormonal regulations of bone (re)modeling is exerted
by the sex steroid hormones that are necessary to maintain
bone integrity (Khosla et al., 2001; Nakamura et al., 2007; Riggs796 Cell 144, 796–809, March 4, 2011 ª2011 Elsevier Inc.et al., 1998). The biological importance of this regulation is best
exemplified by the fact that gonadal failure triggers bone
loss and causes osteoporosis in postmenopausal women
(Manolagas et al., 2002; Rodan and Martin, 2000). To date,
the study of the interplay between gonads and bone has
focused on the mechanism whereby sex steroid hormones
affect bone mass accrual (Manolagas et al., 2002; Nakamura
et al., 2007).
Based on physiological and clinical observations, we hypoth-
esized 10 years ago that bone mass, energy metabolism, and
reproduction might be coordinately regulated (Ducy et al.,
2000). Testing this hypothesis revealed that bone is an endocrine
organ favoring whole-body glucose homeostasis and energy
expenditure. These functions of bone are mediated by an osteo-
blast-specific secreted molecule, osteocalcin, that, when uncar-
boxylated, acts as a hormone favoring b cell proliferation, insulin
secretion, and sensitivity and energy expenditure (Lee et al.,
2007). A second gene expressed in osteoblasts, Esp, inhibits
endocrine functions of osteocalcin by favoring, through an indi-
rect mechanism, its carboxylation (Ferron et al., 2010; Fulzele
et al., 2010). Despite these findings, basic facts about how os-
teocalcin performs its endocrine function are unknown. Most
importantly, the receptor for osteocalcin remains to be deter-
mined, as do the signaling pathways triggered by this hormone
in target cells.
We now show that osteocalcin, in addition to its endocrine
role as a regulator of energy homeostasis, favors male fertility.
It does soby promoting synthesis by Leydig cells of testosterone,
a steroid hormone that is required for many aspects of testicular
function (SinhaHikimandSwerdloff, 1999;Walker, 2009) and has
no effect on female fertility. Furthermore, we identify a bona fide
receptor for osteocalcin that is expressed and transduces its
signal in Leydig cells. Using this tool, we identify genes whose
expression is regulated by osteocalcin in these cells and that
account for its regulation of male fertility. Our findings expand
the biological importance of osteocalcin, begin to unravel its
molecular mode of action, and provide the first evidence that
the skeleton is an endocrine regulator of fertility.
RESULTS
Osteoblasts Enhance Testosterone Production
by Leydig Cells
In an effort to determine whether osteoblasts or any other cells of
mesenchymal origin may regulate the functions of gonads, we
asked whether supernatants of mesenchymal cell cultures affect
hormoneproduction by testes and/or ovaries (Figure 1A). In a first
set of exploratory experiments, we observed that, of all those
tested, the supernatant of osteoblast cultures increased testos-
terone secretion by testes explants to the largest extent (>3-fold)
but did not affect estradiol and progesterone secretion by testes
or ovaries (Figures 1B–1G). In subsequent experiments, testes
explants were replaced by defined cell populations. Because
testosterone is produced by Leydig cells, we asked whether
osteoblast-derived molecule(s) act(s) directly on Leydig cells
by culturing mouse primary Leydig cells in the presence or
absence of supernatants of osteoblast cultures or of other
mesenchymal cell type cultures. In the conditions of this assay,
supernatants of osteoblast cultures were also the only ones
that were able to significantly increase testosterone production
by Leydig cells (>4-fold) (Figure 1H). These experiments indicate
that osteoblasts are the cells of mesenchymal origin that affect
testosterone biosynthesis to the largest extent and that they
do so through secreted molecule(s) acting on Leydig cells of
the testis. This endocrine function of osteoblasts was restricted
to androgen production.
Osteocalcin Favors Male Fertility by Enhancing
Testosterone Production
Osteocalcin is a major osteoblast-derived hormone. We had
previously noticed thatOsteocalcin-deficientmalemice (Ocn/)
breed poorly (P.D. and G.K., unpublished data), so we tested
whether it could be a, or the, osteoblast-derived hormone
enhancing testosterone secretion by Leydig cells.
Several lines of evidence indicated that that is the case. First,
supernatants of wild-type (WT), but not of Ocn/, osteoblast
cultures increased testosterone production by Leydig cells (Fig-
ure 2A). Second, treating Leydig cells with an increasing amount
of uncarboxylated osteocalcin, the active form of the hormone,
resulted in a dose-dependent increase in testosterone secretion,
although at high concentration, the stimulatory effect of osteo-
calcin weakened (Figure 2B). Third, injection of osteocalcin in
WTmice increased circulating levels of testosterone (Figure 2C).
Fourth, we analyzed loss- (Ocn/ mice) and gain-of-function
(Esp/ mice) mouse models for osteocalcin (Lee et al., 2007).
When Ocn/ males were crossed with WT female mice, the
size of the litters was nearly 2-fold smaller than when WT males
were crossed with WT females (Figure 2D). Conversely, the
number of pups per litter was increased when Esp/ males
were bred with WT female mice, although this increase did not
reach statistical significance (Figure 2D). The frequency of litters
for a period of 8 weeks was also decreased in the case of the
loss-of-function model and increased in the gain-of-function
model (Figure 2E). Testes size and weight were significantly
decreased in Ocn/ and increased in Esp/ mice at 3 months
of age. In some of the latter mutant mice, this was caused, in
part, by fluid accumulation (Figures 2F and 2G). The weights ofepididymides and seminal vesicles and sperm count were also
significantly decreased in Ocn/ and increased in Esp/
mice (Figures 2H–2J). These abnormalities worsened over time
(Figures 2G and 2J).
Motility of sperm from both WT and Ocn/ males was as-
sessed by videomicroscopy immediately after dissemination
from the caudal epididymis or after 2 hr of incubation under
conditions known to prepare sperm for fertilization (Sua´rez and
Osman, 1987). In both cases, the percentage of motile sperm
did not differ betweenOcn/ andWTmice (Figure S1A available
online). Likewise, the percentage of abnormally shaped or dead
sperm was similar in WT and Ocn/ mice (Figures S1B and
S1C).
Consistent with the fact that osteocalcin favors testosterone
synthesis in Leydig cells ex vivo, circulating levels of testos-
terone were markedly decreased in Ocn/ and increased in
Esp/ mice at all time points tested (Figure 2K). Accordingly,
circulating levels of luteinizing hormone (LH), a pituitary-derived
hormone favoring testosterone synthesis, was increased
2.5-fold in Ocn/ mice (Figure 2L). Taken together, these cell
biological and genetic experiments identify osteocalcin as
a secreted molecule favoring male fertility by increasing testos-
terone production by Leydig cells.
Circulating progesterone levels were similar inOcn/ andWT
mice, and although circulating levels of estradiol were higher in
Ocn/ than in WT mice, they remained within the normal range
(from 9.3 to 28.9 ng/ml for nonbreeder mice and from 14.4 to
71.1 ng/ml for breeder mice) (Figure 2K). Estradiol levels were
not affected in Esp/ mice. As predicted by the coculture
assays, female fertility, ovary weight, morphology of the uterus,
follicles number, and circulating levels of sex steroid hormones
were normal in Ocn/ female mice (Figures S1D–S1L).
Osteocalcin Regulates Male Fertility
as an Osteoblast-Derived Hormone
To verify that osteocalcin regulates male fertility as an osteo-
blast-secreted hormone and not as a testis-secreted factor,
we performed gene expression and cell-specific gene deletion
experiments.
When assessing Osteocalcin expression by quantitative
PCR (qPCR), we observed that it was more than 750-fold higher
in bone than in gonads; accordingly, we failed to detect
Osteocalcin transcript or protein in testes by in situ hybridization
or western blot analyses (Figures 3A–3C). To be able to trace
Osteocalcin-expressing cells in vivo, we knocked the mCherry
fluorescent reporter gene into the Ocn locus (Ocn-mCherry
mice) (Figures S2A and S2B). Though we observed the expected
strong signal in osteoblasts, there was no detectable mCherry
fluorescence in testes (Figure 3D). Thus, in multiple assays, we
failed to detect Osteocalcin expression in testes.
Next, we generated cell-specific loss- and gain-of-function
models of osteocalcin by crossing mice harboring floxed alleles
of Ocn (Figures S2C and S2D) or Esp with either the a1(I)
Collagen-Cre transgenic mice or the Cyp17-iCre transgenic
mice to delete genes in osteoblasts or in Leydig cells only,
respectively (Bridges et al., 2008; Dacquin et al., 2002). Testes
size and weight, epididymides and seminal vesicles weights,
sperm count, and circulating testosterone levels were allCell 144, 796–809, March 4, 2011 ª2011 Elsevier Inc. 797
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Figure 1. Osteoblasts Enhance Testosterone Biosynthesis by Leydig Cells
(A) Schematic representation of the cell-based assay used to determine the role of various mesenchymal cells in sex steroid hormone production. Various
primary mesenchymal cells from mice were cultured in Leydig cell medium, and supernatants were collected after 24 hr. Then, testis or ovary explants or
primary Leydig cells were cultured for 1 hr with these supernatants, and radioimmunoassays (RIAs) were performed to measure levels of testosterone,
estradiol, or progesterone.
(B–D) Testis explants cultured in the presence of supernatants of different mesenchymal cell cultures: RIA measurement of (B) testosterone, (C) estradiol, and (D)
progesterone levels.
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Figure 2. Osteocalcin Favors Male Fertility by Increasing Testosterone Production by Leydig Cells
(A) Testosterone production by primary Leydig cells cultured in the presence of supernatants of wild-type (WT) or Ocn/ osteoblast cultures.
(B) Testosterone production by primary Leydig cells following stimulation with increasing doses of osteocalcin.
(C) Circulating testosterone levels in WT mice 1 hr, 4 hr, and 8 hr after vehicle or osteocalcin injection (3 ng/g of body weight).
(D and E) Comparison between the average litter size (D) and frequency (E) generated by WT, Ocn/, or Esp/male littermate mice crossed with WT females
(breeding was tested from 8 to 16 weeks of age).
(F–J) Testis size (F), testis weight (G), epididymis weight (H), seminal vesicle weights (I), and sperm counts (J) in Ocn/ and Esp/ compared to WT nonbreeder
littermate mice.
(K) Circulating sex steroid levels in Ocn/ and Esp/ compared to WT littermate mice. The analyses were performed on breeder and nonbreeder mice.
(L) Circulating LH levels in Ocn/ compared to WT nonbreeder littermate mice.
Error bars represent SEM. Student’s t test; *p < 0.05; **p < 0.001. See also Figure S1.reduced in 12-week-old Ocnosb
/ mice. None of these param-
eters were affected in mice lacking Osteocalcin in Leydig cells
only (Figures 3E–3I). There was a tight correlation between circu-
lating levels of osteocalcin and testosterone in Ocnosb
/ mice(E–G) Ovary explants cultured in the presence of supernatants of different mesenc
progesterone levels.
(H) Testosterone production by primary Leydig cells cultured in the presence of
Error bars represent SEM. Student’s t test; *p < 0.05.(Figure 3J). Conversely, Esposb
/ mice displayed testicular
abnormalities identical to those of Esp/ mice. Inactivation of
Esp in Sertoli cells, where this gene is expressed (Dacquin
et al., 2004; Jamin et al., 2003), had no detectable deleterioushymal cells cultures: RIAmeasurement of (E) testosterone, (F) estradiol, and (G)
supernatants of different mesenchymal cell cultures.
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Figure 3. Osteocalcin Promotes Male Fertility through Its Expression in Osteoblasts
(A) qPCR analysis of Osteocalcin expression in bone, testes, and ovaries of 3-month-old nonbreeder WT mice.
(B) Western blot analysis of osteocalcin in femur, calvaria, and testis.
(C) In situ hybridization analysis of Osteocalcin expression in bone and testis of 3-month-old WT mice. Arrows show the Osteocalcin expression in bone.
(D) Analysis of mCherry fluorescent protein in bone and testis of Osteocalcin-mCherry knockin mice. Arrows show the presence of mCherry fluorescent protein
reflecting Osteocalcin.
(E–H) Fertility in mice lacking Ocn specifically in osteoblasts (Ocnosb
/) or Leydig cells (OcnLeydig
/) compared to WT nonbreeder littermates: (E) testes weight,
(F) sperm count, (G) epididymis, and (H) seminal vesicle weights.
(I) Ratio of circulating testosterone levels measured in WT and Ocnosb
/ or in WT and OcnLeydig
/ nonbreeder littermate mice.
(J) Linear regression representation of circulating testosterone levels versus circulating osteocalcin levels in Ocnosb
/ (n = 11) nonbreeder mice. Each dot
represents one Ocnosb
/ mouse. In WT littermate mice, the levels of osteocalcin varied from 106 to 177 ng/ml (on average, 133 ng/ml). For Ocnosb
/, the
average osteocalcin level was 68.4 ng/ml.
(K–M) Fertility inmice lacking Esp specifically in osteoblasts (Esposb
/) or Leydig cells (EspLeydig
/) compared toWT nonbreeder littermates: (K) testis weight, (L)
sperm count, and (M) seminal vesicle weight.
(N) Ratio of circulating testosterone levels measured in WT and Esposb
/ or in WT and EspLeydig
/ nonbreeder littermate mice.
Error bars represent SEM. Student’s t test; *p < 0.05; **p < 0.001. See also Figure S2.consequence on testis biology, demonstrating that it is through
its expression in osteoblasts, not in Sertoli cells, that Esp regu-
lates male fertility (Figures 3K–3N). These experiments therefore
indicate that it is only through its expression in osteoblasts that
osteocalcin promotes male fertility.
Cellular and Molecular Bases of Osteocalcin Regulation
of Male Fertility
To address this aspect of osteocalcin biology, we first studied the
morphology of Leydig cells by immunostaining of 3-b-hydroxyste-800 Cell 144, 796–809, March 4, 2011 ª2011 Elsevier Inc.roiddehydrogenase (3b-HSD). The number of Leydig cellswas not
significantly affected by the absence of osteocalcin or Esp, nor
was the expression of genes affecting cell proliferation (Figure 4A
anddatanot shown).However, Leydig cells appearedhypotrophic
inOcn/ testes, as determined by the significant decrease of the
ratio between the Leydig cells and interstitial areas observed in
Ocn/ compared to WT testes (Figures 4B and 4C). Conversely,
this ratio was increased in Esp/ testes (Figures 4B and 4C).
When germ cells were analyzed through a stereological
approach, we observed that the number of spermatocytes and
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Figure 4. Cellular and Molecular Events Triggered by Osteocalcin in Leydig Cells
(A–C) Histological analyses of Leydig cells in Ocn/ and Esp/ nonbreeder mice. (A) Absolute number of Leydig cells per testis was quantified by the number
of 3b-HSD-positive cells. (B) Ratio between Leydig cells (immunopositive for 3b-HSD) versus testis interstitial areas inWT,Ocn/, and Esp/ nonbreeder mice.
(C) 3b-HSD immunohistochemistry staining of WT, Ocn/, and Esp/ testes.
(D) Quantification of the different testicular cell types in WT and Ocn/ nonbreeder mice.
(E) Germ cell apoptosis analysis by TUNEL assay in WT, Ocn/, and Esp/ nonbreeder testes.
(F–H) qPCR analysis of the expression of steroidogenic acute regulatory protein (StAR), cholesterol side-chain cleavage enzyme (Cyp11a), cytochrome P-450 17
a (Cyp17), 3-b-hydroxysteroid dehydrogenase (3b-HSD), aromatase enzyme (Cyp19), and 17-b-hydroxysteroid dehydrogenase (HSD-17) in primary Leydig
cells treated with 3 ng/ml of osteocalcin (F), in Ocn/ compared to WT nonbreeder littermate testes (G), and in Esp/ compared to WT nonbreeder littermate
testes (H).
(I) qPCR analysis of Grth/Ddx25 expression in WT, Ocn/, Esp/, and WT nonbreeder mice treated with vehicle or osteocalcin (3 ng/g of body weight).
(J) Western blot analysis of cleaved caspase 3 and tACE in WT and Ocn/ nonbreeder testes.
Error bars represent SEM. Student’s t test; *p < 0.05; **p < 0.001. See also Figure S3.round spermatids was significantly decreased in Ocn/ mice
(Figure 4D). Consistently, the size of the epithelium in testis
tubules was also significantly decreased in these mutant mice,
a feature suggesting that osteocalcin regulates, presumably
through its effect on testosterone biosynthesis, germ cell
number (Figure S3B). Because testosterone inhibits germ cell
apoptosis (Brinkworth et al., 1995; Henrikse´n et al., 1995; Sinha
Hikim and Swerdloff, 1999), we performed TUNEL assays. Thoseshowed a 2-fold increase in germ cell apoptosis in Ocn/
compared to WT mice and a 2-fold decrease in Esp/ testes
(Figure 4F). Importantly, there was an increase in the number
of apoptotic cells in stages VI–VIII of the spermatogenic cycle,
the very stages of spermatogenesis in which testosterone
affects germ cell apoptosis more efficiently (Sharpe et al.,
1992) (Figure S3C). There were, on the other hand, no abnormal-
ities of germ cell proliferation in either Ocn/ or Esp/ miceCell 144, 796–809, March 4, 2011 ª2011 Elsevier Inc. 801
(Figure S3A). Taken together, these data further indicate that the
decrease in fertility demonstrated by Ocn/ male mice is
caused by a decrease in testosterone levels.
To determine how osteocalcin favors testosterone synthesis
by Leydig cells, we tested whether it affects expression of the
enzymes that are necessary for testosterone biosynthesis such
as StAR, Cyp11a, Cyp17, and 3b-HSD. In cell culture, uncar-
boxylated osteocalcin increased expression of these genes in
Leydig cells (Figure 4F). Accordingly, their expression was signif-
icantly decreased in Ocn/ and increased in Esp/ testes
(Figures 4G and 4H), whereas it was unaffected in Ocn/ and
Esp/ ovaries or adrenal glands (Figures S3D–S3G). Of note,
there was no change in expression of Cyp19, the gene encoding
the testosterone aromatase, or of HSD-17 inOcn/ and Esp/
testes (Figures 4F–4H).
To further support the notion that osteocalcin influences germ
cell apoptosis through testosterone, we examined expression of
Gonadotropin Regulated Testicular Helicase (Grth) because this
gene has emerged as an essential regulator of spermatogenesis
that inhibits germ cell apoptosis and whose expression in germ
cells and Leydig cells is regulated by testosterone (Dufau and
Tsai-Morris, 2007; Tsai-Morris et al., 2007, 2010). Grth expres-
sion was decreased in Ocn/ and increased in Esp/ testes
(Figure 4I). GRTH inhibits activation of caspase 3, a determinant
of apoptosis (Sheng et al., 2006), and favors expression of tACE,
a protein favoring germ cell maturation. Consistent with these
notions, western blot analyses showed an increase of cleaved
caspase 3 accumulation and a decrease of tACE in Ocn/
testes (Figure 4J).
Gprc6a, a G Protein-Coupled Receptor, Transduces
Osteocalcin Signal in Leydig Cells
To begin to elucidate the molecular mode of action of osteocal-
cin, we next searched for a receptor expressed in Leydig cells
that could transduce its signal. To that end, we used a two-
step experimental strategy, taking advantage of the fact that
osteocalcin regulates fertility only in male mice.
First, we defined the signal transduction pathway used by
osteocalcin (these experiments were performed in TM3 cells,
and not primary Leydig cells, in order to obtain a sufficient
amount of extract for analysis). With this aim, we treated the cells
with uncarboxylated osteocalcin and assayed for tyrosine phos-
phorylation, ERK activation, intracellular calcium accumulation,
and cAMP production, using in each case an appropriate posi-
tive control. Osteocalcin consistently induced cAMP production
in Leydig cells to a level comparable to that induced by human
chorionic gonadotropin, the positive control, but did not induce
tyrosine phosphorylation, ERK activation, or intracellular calcium
accumulation in these cells (Figures 5A–5D). At higher concen-
trations, osteocalcin stimulation of cAMP production weakened.
These data implied that the osteocalcin receptor may be a G
protein-coupled receptor (GPCR). Hence, in the second step of
this experimental strategy, we took advantage of the dichotomy
of function of osteocalcin betweenmales and females and asked
how many orphan GPCRs were expressed in testes at a level at
least 5-fold higher than in ovary. Twenty-two out of 103 orphan
GPCRs tested were predominantly expressed in testes; of these
22, four were enriched in Leydig cells (Figures 5E and 5F). Among802 Cell 144, 796–809, March 4, 2011 ª2011 Elsevier Inc.them, Gprc6a caught our attention because its deletion in all
cells results in a metabolic and fertility phenotype similar to
that of Ocn/ mice (Pi et al., 2008).
Immunofluorescence experiments verified that Gprc6a is
expressed in Leydig cells in testes, but not in follicular cells of
the ovary. Importantly, the same is true in human gonads
(Figures 5G and 5H and Figure S4B). Postnatally, Gprc6a
expression peaked within the first week of life, when circulating
testosterone levels are elevated. Gprc6a expression then
decreased before increasing again at 6 weeks of age, when
circulating levels of testosterone also rebound (Figure 5I). We
also performed binding assays on mouse testes using biotiny-
lated osteocalcin as a ligand. In the conditions of this assay, os-
teocalcin bound to Leydig cells and the specificity of this binding
was confirmed by several criteria. First, there was no signal when
using avidin-biotin alone; second, there was no signal either in
other cellular compartments of the testicular tubules; third, we
could not detect any binding when using Gprc6a-deficient
testes; fourth, osteocalcin binding could be competed away by
an excess (100-fold) of unlabeled osteocalcin, but not by the
same excess of hCG or of other molecules proposed as ligands
of Gprc6a (Wellendorph et al., 2005) (Figure 5J). These data iden-
tify Gprc6a as an osteocalcin receptor in Leydig cells.
To define Gprc6a function in Leydig cells in vivo, we generated
Gprc6aLeydig
/ mice. Prior to analyzing these Gprc6aLeydig
/
mice, we verified that we had deleted Gprc6a, albeit partially
(75% of deletion), in Leydig cells, but not in other organs (Figures
S5C and S5D). In Gprc6aLeydig
/ male mice, testes size and
weight, epididymis and seminal vesicle weights, sperm counts
and circulating testosterone levels, and Leydig cell area were
all reduced, as was the expression of Grth and the three genes
controlling testosterone biosynthesis that are regulated by
osteocalcin (Figures 6A–6I and Figure S5E). Accordingly, the
number of apoptotic germ cells was increased compared to
WT testes (Figure 6J). To establish genetically that Gprc6a is
a signaling receptor for osteocalcin in Leydig cells, we analyzed
compound mutant mice lacking one allele of Ocn and one allele
of Gprc6a in Leydig cells only (Ocn+/;Gprc6aLeydig
+/ mice).
Whether we looked at testes, epididymis and seminal vesicle
weights, or sperm count, Ocn+/;Gprc6aLeydig
+/ mice had
a phenotype identical to that observed in Gprc6aLeydig
/ and
Ocnosb
/ mice (Figures 6A–6I).
CREB Is a Transcriptional Effector of Osteocalcin
Signaling in Leydig Cells
Observations that osteocalcin treatment of Leydig cells
increased cAMP production and that the osteocalcin receptor
is a GPCR suggested that CREB could mediate osteocalcin
functions in these cells. In support of this hypothesis, osteocalcin
treatment of Leydig cells favors CREB phosphorylation (Fig-
ure 7A). To investigate this further, we generated mice that
lack CREB expression specifically in Leydig cells (CrebLeydig
/
mice).
Twelve-week-old CrebLeydig
/ male mice displayed a reduc-
tion in testis size and weight, in epididymides and seminal vesi-
cles weights, in sperm count, and in circulating testosterone
levels similar to those seen in Ocn/ and Gprc6aLeydig
/ mice
(Figures 7B–7G and Figure S6). CrebLeydig
/ mice also
**
*
*
*
*
*
*
*
*
*
8.0
0
4.0
6.0
2.0
10.0
12.0
c
A
M
P
 P
r
o
d
u
c
t
io
n
(
p
m
o
l/
1
0
7
c
e
ll
s
)
D
**
**
2.0
0
1.0
3.0
F
lu
o
r
e
s
c
e
n
c
e
 c
h
a
n
g
e
(
f
o
ld
 o
v
e
r
 b
a
s
e
li
n
e
)
C
4.0
10 20 30 40 50 60 70
Control
Ionophore
10% FBS
3ng/ml Osteocalcin
6ng/ml Osteocalcin
600ng/ml Osteocalcin
1μg/ml Osteocalcin
30ng/mlOsteocalcin
A B
J
b-OsteocalcinControl
b-Osteocalcin
+Osteocalcin
b-Osteocalcin
+hCG
b-Osteocalcin
WT WT
WTWT
Gprc6a-/-
WT
5 15 30 60
+Vehicle +Osteocalcin
ERK
42
**
1
n
g
3
 n
g
h
C
G
1
0
 n
g
0
 n
g
I
8.0
0
4.0
6.0
2.0
10.0
G
p
r
c
6
a
G
p
c
r
s
E
x
p
r
e
s
s
io
n
 i
n
 L
e
y
d
ig
 C
e
ll
s
 R
e
la
t
iv
e
 t
o
 T
e
s
t
is
  
(
F
o
ld
)
G
p
r
4
5
G
p
r
1
1
2
G
p
r
1
3
9
Testis
Leydig cells
44
44pERK
5 15 30 60
4.0
0
2.0
1
 W
e
e
k
G
p
r
c
6
a
E
x
p
r
e
s
s
io
n
 i
n
 T
e
s
t
is
(
R
e
la
t
iv
e
 t
o
 4
 W
e
e
k
-
o
ld
)
4
 W
e
e
k
s
6
 W
e
e
k
s
1
2
 W
e
e
k
s
6.0
8.0
10.0
*
*
F
150
250
75
100
37
50
V
e
h
ic
le
1
 n
g
3
 n
g
1
0
 n
g
F
B
S
In
s
u
li
n
Anti-Gprc6a
Anti-IgG
H
50
**
Orphans GPCR (n=103)
Testis enriched orphan 
GPCR (n=22)
Leydig cells enriched 
orphan GPCR (n=4)
E
β-actin
pTyrosine
b-Osteocalcin
+Lysine
5 15 30 60
+Vehicle +Osteocalcin
5 15 30 60
FBS
FBS
G
p
r
c
6
a
 R
e
la
t
iv
e
 
E
x
p
r
e
s
s
io
n
 i
n
 h
u
m
a
n
 (
%
) Testis
Ovary
80
0
40
60
20
100
Anti-Gprc6a
Anti-IgG
Mouse Human
G
Figure 5. G Protein-Coupled Receptor Gprc6a Is a Receptor for Osteocalcin
(A) Anti-phosphotyrosine antibody western blot analysis of TM3 Leydig cells treated with increasing concentrations of osteocalcin, or 10% FBS or insulin as
positive controls, for 1 min (top). Proteins phosphorylated on tyrosine residues appear in positive controls (asterisks), but not in osteocalcin-treated cells. Equal
loading was assessed using an anti-actin antibody (bottom).
(B) Western blot analysis of TM3 Leydig cells showing the absence of ERK1/2 phosphorylation upon stimulation with vehicle or osteocalcin.
(C) Calcium fluxes in primary Leydig cells upon stimulation with increasing doses of osteocalcin. 10% FBS and ionophore (A23187) were used as positive
controls.
(D) cAMP production upon osteocalcin stimulation is increased in TM3 Leydig cells.
(E) Schematic representation of the results obtained by the differential expression search for osteocalcin receptors. Among the 103 orphan GPCRs expressed in
testis and ovary, 22 were predominantly expressed in testis, and only four were enriched in primary Leydig cells compared to the expression in whole testis.
(F) Relative expression of Gprc6a, Gpr45, Gpr112, and Gpr139 in Leydig cells compared to whole testis.
(G) qPCR analysis of Gprc6a expression in human testis and ovary.
(H) Immunofluorescence analysis of Gprc6a expression in mice and human testis coronal sections. Anti-IgG was used as negative control.
(I) qPCR analysis of Gprc6a expression in 1-, 4-, 6-, and 12-week-old WT testes.
(J) Cross-sections of testes from WT and Gprc6a-deficient mice stained with biotinylated osteocalcin (b-osteocalcin). (Upper-left) WT testis stained with avidin-
biotin complex only. (Upper-middle) WT testis stained with 10 nM of b-osteocalcin. (Upper-right) Testis from Gprc6a-deficient mice stained with 10 nM of
b-osteocalcin. (Lower-left) WT testis stained with 10 nM of b-osteocalcin in the presence of 1000 nM hCG. (Lower-middle) WT testis stained with 10 nM of
b-osteocalcin in the presence of 1000 nM lysine. (Lower-right) WT testis stained with 10 nM of b-osteocalcin in the presence of 1000 nM of unlabeled osteocalcin.
Error bars represent SEM. Student’s t test; *p < 0.05, **p < 0.001. See also Figure S4.demonstrated a strong decrease in the expression ofGrth and of
the four genes involved in testosterone biosynthesis whose
expression is regulated by osteocalcin (Figures 7H and 7I). In
agreement with these data, CREB could bind to the promoterregions of Cyp11a, 3b-HSD, and StAR (Zhang et al., 2005) (Fig-
ure 7J). To establish whether CREB acts downstream of Gprc6a
in Leydig cells to regulate male fertility, we generated compound
heterozygous mice lacking one copy of Creb and one copy ofCell 144, 796–809, March 4, 2011 ª2011 Elsevier Inc. 803
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Figure 6. Specific Deletion of Gprc6a in Leydig Cells Decreases Male Fertility
(A–E) Fertility in mice lacking Gprc6a in Leydig cells only (Gprc6aLeydig
/) or lacking one allele of Ocn or one allele of Gprc6a in Leydig cells only (Ocn+/ or
Gprc6aLeydig
+/) or in compound heterozygous mice (Ocn+/; Gprc6aLeydig
+/) compared to control littermates. (A) Testis size, (B) testis weight, (C) sperm count,
and (D and E) epididymis and seminal vesicle weights.
(F) qPCR analysis of Grth expression in mice of indicated genotypes.
(G) Ratio between Leydig cells (stained by immunohistochemistry of 3b-HSD) versus testis interstitial areas.
(H) Ratio of circulating testosterone levels measured in WT and Gprc6aLeydig
/ mice.
(I) qPCR analysis of StAR, Cyp11a, and 3b-HSD in Gprc6aLeydig
/ and Ocn+/; Gprc6aLeydig
+/ compared to WT littermate testes.
(J) Germ cell apoptosis analysis by TUNEL assay.
All of the analyses were performed in nonbreeder mice. Error bars represent SEM. Student’s t test; *p < 0.05; **p < 0.001. See also Figure S5.
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Gprc6a in Leydig cells. The decrease in fertility demonstrated by
CrebLeydig
+/;Gprc6aLeydig
+/ male mice was similar to that
observed in CrebLeydig
/ or Gprc6aLeydig
/ male mice (Figures
7B–7F and 7H) and was not observed in single-heterozygous
mutant mice (data not shown). These results identify CREB as
a transcriptional mediator of osteocalcin regulation of testos-
terone biosynthesis in Leydig cells.
DISCUSSION
This study reveals that bone is a positive regulator of male
fertility. This interaction is mediated through the osteoblast-
derived hormone osteocalcin, which binds to a specific receptor
that is present on Leydig cells of the testes and favors testos-
terone biosynthesis (Figure 7K). Our results, along with those
previously published, support the hypothesis that regulation of
bone remodeling, energy metabolism, and reproduction are
linked (Ducy et al., 2000; Lee et al., 2007). They also demonstrate
that bone is a more important regulator of whole-organism phys-
iology than was anticipated.
In the last 10 years, the view of bone as a mere assembly of
inert calcified tubes has evolved because two independent lines
of investigation painted a much more dynamic picture of this
tissue. First, the dialog between bone physiology and energy
metabolism and the paramount influence of the brain in the
control of bone mass accrual became apparent (Karsenty,
2006). Second, it has been realized that bone is an endocrine
organ regulating at least two functions, phosphate metabolism
and energy homeostasis, through two distinct osteoblast-
derived hormones, FGF23 and osteocalcin (Fukumoto and Ya-
mashita, 2007; Lee et al., 2007). These two endocrine functions
of bone begged the following question: are these the only func-
tions affected by bone in its endocrine capacity?
The well-known regulation of bone remodeling by gonads
provides an ideal setting to address this question and raises
the possibility that bone, in its endocrine capacity, could influ-
ence through a feedback mechanism reproductive functions in
either gender. We show here that osteoblasts, the bone-forming
cells, favor through osteocalcin fertility in male, but not female,
mice. Our observation that Ocn/ mice have low circulating
testosterone levels despite an increase in circulating LH levels
may have several explanations. For instance, it could be that
deletion of osteocalcin causes, for unknown reasons, a loss of
negative feedback. Alternatively, it may also suggest that LH
cannot favor testosterone production in the absence of osteo-
calcin. Further experiments will be required to address this point.
All of our experiments conducted ex vivo and in vivo in loss-
and gain-of-function models indicate that the main mechanism
whereby osteocalcin favors male fertility is by increasing testos-
terone synthesis in Leydig cells. Testosterone, in turn, supports
maturation and prevents apoptosis of germ cells (Henrikse´n
et al., 1995; Sinha Hikim and Swerdloff, 1999; Walker, 2009).
Because there is no expression of Gprc6a in Sertoli cells or
germ cells, it is likely that osteocalcin regulates male fertility by
binding to its receptor on Leydig cells. This was confirmed by
the analysis of the Leydig cell-specific deletion of Gprc6a and
Creb. Testosterone affects germ cell survival by involving other
cell types such as Sertoli cells because germ cells do notexpress androgen receptor (Bremner et al., 1994; De Gendt
et al., 2004; Wang et al., 2003). Unexpectedly, Ocn/ male
mice have a higher level of circulating estrogen than WT litter-
mates, even though osteocalcin does not promote estradiol
synthesis. The most likely explanation for this mild increase in
circulating estradiol levels in theOcn/mice is that the increase
in the number of adipocytes caused by Osteocalcin inactivation
may result in an increase in the aromatization of testosterone into
estrogen in fat (Nelson and Bulun, 2001; Simpson et al., 2000;
Simpson, 2003). Importantly, this was also observed in mice
lacking Gprc6a (Pi et al., 2008).
The existence of such a profound influence exerted by
a hormone other than LH on sex steroid hormone synthesis rai-
ses the question of whether it is amale-specific phenomenon. To
date, we have no evidence that, at least in the mouse, the skel-
eton favors estrogen production in females. This, however, does
not rule out the possibility that other peripheral organs may
secrete hormones favoring estrogen synthesis.
The growing number of functions identified for osteocalcin
makes the identification of its receptor all the more important.
An unbiased approach based on the ability of osteocalcin to
increase cAMP production in Leydig cells and on its dichotomy
of function between male and female gonads led to the identifi-
cation of Gprc6a as the osteocalcin receptor. This orphan
receptor, which belongs to the C family of GPCRs (Wellendorph
and Bra¨uner-Osborne, 2004), has been proposed to be
a receptor for amino acids, for calcium in the presence of osteo-
calcin as a cofactor, and for androgen (Pi et al., 2005, 2008,
2010). Yet, the possibility that Gprc6a could be a specific
receptor for osteocalcin has never been tested through
biochemical or genetic means. Here, we provide biochemical
and genetic evidence establishing its identity as a specific
receptor for osteocalcin in Leydig cells, though we failed to
detect an interaction between amino acids and Gprc6a. That
Gprc6a is expressed in human and mice Leydig cells in the
testes, but not in follicular cells of ovaries, provides a molecular
basis for the fact that osteocalcin affects male fertility only. The
expression of this receptor is extremely dynamic and peaks at
adulthood when testosterone biosynthesis is at its maximum
(Feldman et al., 2002; Gray et al., 1991; Quigley, 2002). This
observation suggests that the regulation of osteocalcin functions
occurs, at least in part, by regulating the expression of its
receptor. The identification of an osteocalcin receptor opens
the door to a thorough molecular dissection of the mode of
action of osteocalcin in various cell types where it is expressed.
This may eventually lead to the identification of additional func-
tions for osteocalcin.
An obvious question raised by this study is whether the skel-
eton also regulates male fertility in humans. In the absence of
inactivating mutations in the Osteocalcin or Gprc6a genes in
humans and of studies correlating circulating levels of uncar-
boxylated osteocalcin and fertility in the aging male population,
this question can only be addressed through indirect means
for now. Although we cannot rule out the possibility that the
endocrinology of reproduction may be different in this particular
aspect between rodents and humans, indirect evidence
suggests that the function of osteocalcin described here may
be conserved in humans. First, and most importantly, this workCell 144, 796–809, March 4, 2011 ª2011 Elsevier Inc. 805
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was, in part, initiated because of a clinical observation made in
humans: loss of sex steroid hormones triggers a decrease in
bone mass. This led us to test whether feedback regulation of
fertility by bone may also occur. Second, Gprc6a is expressed,
in human and in mice, in Leydig cells of the testes, but not in
ovaries. Hence, the entire signaling cascade from the hormone
to the receptor exists in the equivalent organs in humans. Third,
the growing number of reports indicating that osteocalcin is a reli-
able indicator of glucose intolerance, just as it is in mice, strongly
suggests that this molecule also acts as a hormone in humans
(Kanazawa et al., 2010; Saleem et al., 2010; Yeap et al., 2010).
Along these lines, there is no example yet of a molecule being
a hormone in themouse that has abruptly lost this attribute in hu-
mans. This is, nevertheless, an aspect of osteocalcin that will
need further investigation in the future.
EXPERIMENTAL PROCEDURES
Mice Generation
All experiments were performed on the 129-Sv (Taconic) genetic background.
Control littermates were used in all experiments. Mice genotypes were deter-
mined by PCR; primer sequences are available upon request. Osteocalcin-
mCherry knockin, Ocn conditional, and Gprc6a conditional allele generation
strategies are described in Figure S2 and Figure S5.
Primary Leydig Cells and Testes Explant Preparation
Adult mouse Leydig cells were isolated by mechanical dissociation of the
testes followed by purification on a 0%–90% Percoll gradient (Hunter et al.,
1982; Schumacher et al., 1978). Primary Leydig cells were cultured in Minimal
Essential Medium (MEM + GlutaMAX, Invitrogen) supplemented with 13 Pen-
Strep, 25 mM HEPES (pH 7.4), and 0.07% BSA at 33C in 5% CO2. After 3 hr
of attaching and starvation, cells were washed once with culture medium
and then used for experiments. The testes explant preparation protocol was
adapted from (Powlin et al., 1998). Explants were washed three times with
PBS and placed in serum-free RPMI medium for 2 hr before being used for
experiments.
Osteocalcin Stimulation of Leydig Cells or Testes Explants
Primary Leydig cells and testes explants were washed three times with PBS
and stimulated with different doses of recombinant osteocalcin prepared as
previously described (Ferron et al., 2008) or with hCG as a positive control.
After 1 hr, an aliquot of medium was collected for measurements of testos-
terone. Cells were then maintained for 3 additional hr and lysed in 1 ml TRIZOL
(Invitrogen) for RNA isolation.
Sperm Counts and Hormone Measurements
Caudal epididymides were minced in 1 ml PBS, and the number of cells
released was counted after 1 hr. The total sperm count was assessed in the
final suspension by using a hemocytometer (Dakhova et al., 2009). Circulating
levels of testosterone, estradiol (E2), and progesterone were measured byFigure 7. CREB Is a Transcription Factor-Mediating Osteocalcin-Evok
(A) Western blot analysis of CREB activation upon stimulation with osteocalcin.
(B–F) Fertility in mice lacking Creb in Leydig cells (CrebLeydig
/) or of compo
littermates. (B) Testis size, (C) testis weight, (D) sperm count, and (E and F) epid
(G) Quantification of circulating testosterone levels represented as fold change c
(H) qPCR analysis of Grth expression in mice of indicated genotypes.
(I) qPCR analysis of StAR, Cyp11a, Cyp17, 3b-HSD, Cyp19, and HSD-17 in Creb
(J) Chromatin immunoprecipitation (ChIP) using anti-CREB antibody and unspec
(K) Model representing current knowledge about the regulation of male fertility b
All of the analyses were performed in nonbreeder mice.
Error bars represent SEM. Student’s t test; *p < 0.05. See also Figure S6.radioimmunoassay (RIA) from Diagnostic Systems Laboratories (Testosterone
RIA DSL-4000, Estradiol RIA DSL-43100, and Progesterone RIA-3900).
Histology
One testis or ovary from each mouse was randomly selected for molecular
analysis, and the other one was used for histology. Specimens were collected,
weighed, and fixed in Bouin’s fixative for histological analyses before being
dehydrated through graded ethanol, processed for paraffin embedding, and
serially sectioned at 5 mm. For histological analysis, testes and ovaries
sections were stained with periodic acid-Schiff and counterstained with hema-
toxylin. TUNEL labeling was performed using the ApopTag Peroxydase In Situ
Apoptosis detection kit (Millipore-S7100). Apoptotic indices were determined
by counting the total number of TUNEL-positive cells or the number of TUNEL-
positive germ cells at different stages (Russell et al., 1990). Approximately 500
tubules were counted on at least four cross-sections located at midtestis for
each animal.
Gene Expression Studies
RNA was purified from tissues, primary Leydig cells, or cultured cells using
TRIZOL (Invitrogen). RNA isolation, cDNA preparation, and qPCR analysis
was carried out following standard protocols. qPCR analyses were performed
using specific quantitative PCR primers from SABiosciences (http://www.
sabiosciences.com/RT2PCR.php).
cAMP Quantification
For cAMP measurements, TM3 Leydig cells were plated in 6 cm dishes (107
cells per dish) 1 day before the experiment. Cells were serum starved for
16 hr (in the presence of 0.1% BSA) and then preincubated in the presence
of 0.5 mM IBMX for 30 min and stimulated with indicated concentration of os-
teocalcin also in the presence of 0.5 mM IBMX for 30min. cAMP concentration
was measured with the Parameter cAMP kit (R&D Systems, KGE002).
Receptor Binding Assays
For binding studies, testes from 8-week-old mice were snap-frozen in liquid
nitrogen, and 20 mm thick sections were prepared and desiccated overnight
at 4C under vacuum. On the following day, sections were rehydrated in ice-
cold binding buffer (50 mM TrisHCl [pH 7.4], 10 mM MgCl2, 0.1 mM EDTA,
and 0.1%BSA) for 15min and incubated for 1 hr in the presence of biotinylated
osteocalcin. For competition assays, a 100-fold molar excess of unlabeled
osteocalcin, glycine, lysine, or hCG was added. After three washes in cold
PBS, sections were incubated for 1 hr in the detection system containing
0.1% BSA (ABC Elite, Vector Laboratories), washed again, and incubated
with DAB peroxidase substrate kit (Vector Laboratories) according to the
manufacturer’s protocol. After a final wash, sections were mounted in water-
based mounting medium. As negative controls, we used sections incubated
with the detection system only (ABC Elite and DAB) or Gprc6a/ testis
sections (Basura et al., 2008).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at doi:10.1016/j.cell.
2011.02.004.ed Gene Expression in Leydig Cells
und heterozygous mice (CrebLeydig
+/; Gprc6aLeydig
+/) compared to control
idymis and seminal vesicle weights.
ompared to WT.
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ific isotype IgG antibody in the TM3 cell line.
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